Dublin, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The "Autoimmune Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.
The "Autoimmune Collaboration and Licensing Deals" report offers a comprehensive understanding and unprecedented access to autoimmune deals entered into by leading biopharma companies worldwide.
The report covers autoimmune deals from 2016 to 2023, providing access to detailed deal payment terms as announced between the parties. Understanding these negotiated deal terms can offer valuable insights into the negotiation process and the expectations for achieving specific terms.
The report contains a comprehensive listing of collaboration and licensing deals announced since 2016, sourced from the Current Agreements deals and alliances database. It includes financial terms when available and provides links to online copies of actual licensing contract documents submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of the report provide an orientation to autoimmune dealmaking and business activities. Chapter 1 introduces the report, while Chapter 2 analyzes the trends in autoimmune dealmaking.
Chapter 3 covers the financial deal terms for autoimmune deals signed in various stages of development, including headline value, upfront payment, milestone payment, and royalty rates.
Chapter 4 reviews the top 25 most active biopharma companies engaged in autoimmune dealmaking. It also includes links to online access of contract agreements published at the SEC via the Current Agreements deals and alliances database.
Chapter 5 offers a comprehensive and detailed review of autoimmune deals signed and announced since 2016, with available contract documents. Each deal title includes a Weblink to an online version of the actual contract document for easy access.
Chapter 6 provides a directory of autoimmune deals organized by therapeutic target.
The report also includes tables and figures that illustrate the trends and activities in autoimmune dealmaking since 2016. Additionally, a comprehensive deal directory is provided, organized by company alphabetically and technology type. Each deal title includes a Weblink to an online version of the deal record and, when available, the contract document for on-demand access.
Autoimmune Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse autoimmune collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Autoimmune Collaboration and Licensing Deals includes:
- Trends in autoimmune dealmaking in the biopharma industry
- Overview of collaboration and licensing deal structure
- Directory of autoimmune deal records covering pharmaceutical and biotechnology
- The leading autoimmune deals by value
- Most active autoimmune licensing dealmakers
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
The report includes coverage of the following autoimmune diseases:
- Multiple sclerosis
- Restless leg syndrome
- Dermatitis
- Eczema
- Alopecia
- Psoriasis
- Celiac disease
- Inflammatory bowel disease
- Crohn's disease
- Ulcerative colitis
- Glomerulonephritis
- Endometriosis
- Immune thrombocytopenic purpura
- Neutropenia
- Graft versus host disease
- Scleroderma
- Systemic lupus erythematosus
- Addison's disease
- Diabetes Type 1
- Ankylosing spondylitis
- Juvenile arthritis
- Psoriatic arthritis
- Rheumatoid arthritis
- Uveitis
- Narcolepsy
- Chronic obstructive pulmonary disease
- Idiopathic pulmonary fibrosis
- Sarcoidosis
- Meniere's disease
For more information about this report visit https://www.researchandmarkets.com/r/egfqvy
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
